Hope Rugo· @hoperugo · X·· 21 hours agoScore70
Body
Binghe Xu presents data from the Healer trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and modest increase in heme tox. Lipo doce approved in US. Today Publ in NEJM! #ESMO2026 @OncoAlert
72 views · 4 likes · 3 reposts · 1 reply
Conference abstracts
LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgReplies in this thread
- Hope Rugo@hoperugo
Interesting to consider how this fits into the ADC TDXd world.
Source: Hope Rugo · x.com